Re: Farmas USA
"Amarin Corp. PLC (NASDAQ:AMRN): Leerink says Amarin’s equity raise announced Monday night removes an overhang, and adds that the company’s Vascepa prescription data were better than expected. The firm reiterates an Outperform rating on the stock with a $20 price target."
AMRN